Immunotherapy of Multiple Myeloma
- Prosjektnummer
- 2015028
- Ansvarlig person
- Bjarne Bogen
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Inflammatory and Immune System
- Forskningsaktivitet
- 5. Treatment Developement
CD4
Cancer Res 2018 Aug 15;78(16):4573-4585. Epub 2018 mai 11
PMID: 29752262
Tumor Killing by CD4
Front Immunol 2018;9():1684. Epub 2018 jul 23
PMID: 30083157
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.
Leukemia 2017 Oct;31(10):2114-2121. Epub 2017 feb 24
PMID: 28232741
Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
Yonsei Med J 2017 May;58(3):505-513.
PMID: 28332354
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Mol Ther Oncolytics 2017 Mar 17;4():31-40. Epub 2016 des 14
PMID: 28345022
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
Haematologica 2016 Feb;101(2):e59-62. Epub 2015 nov 20
PMID: 26589914
IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration.
J Allergy Clin Immunol 2016 May;137(5):1487-1497.e6. Epub 2015 des 2
PMID: 26653800
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.
Leukemia 2016 May;30(5):1216-20. Epub 2015 okt 9
PMID: 26449664
Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response.
Cancer Res 2016 Dec 01;76(23):6864-6876. Epub 2016 sep 12
PMID: 27634753
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Oncotarget 2016 Oct 11;7(41):67175-67182.
PMID: 27626487
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.
Mol Ther Oncolytics 2016;3():16032. Epub 2016 des 7
PMID: 27933316
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Cancer Res 2015 Aug 15;75(16):3268-78. Epub 2015 jun 2
PMID: 26038231
Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.
Leukemia 2015 Sep;29(9):1882-90. Epub 2015 jun 19
PMID: 26159051
Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-? by a T-bet-dependent mechanism.
J Immunol 2015 Jan 15;194(2):827-35. Epub 2014 des 10
PMID: 25505279
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
J Clin Invest 2015 Dec;125(12):4375-90. Epub 2015 okt 26
PMID: 26517694
Mechanistic basis of CD4+ T cell immune responses against cancer
- Disputert:
- juni 2018
- Hovedveileder:
- Bjarne Bogen
APC-targeted DNA vaccines against pandemic influenza
- Disputert:
- februar 2018
- Hovedveileder:
- Bjarne Bogen
Improving antibody responses of sDC1 targeted vaccines
- Disputert:
- mars 2018
- Hovedveileder:
- Bjarne Bogen
CD4+ T cell-induced macrophage cytotoxicity against tumor cells
- Disputert:
- september 2016
- Hovedveileder:
- Bjarne Bogen
- Arnar Gudjonsson Postdoktorstipendiat (finansiert av denne bevilgning)
- Tor Kristian Andersen Postdoktorstipendiat (finansiert av denne bevilgning)
- Marte Hotvedt Fauskanger Doktorgradsstipendiat (finansiert av denne bevilgning)
- Kjartan Hennig Prosjektdeltaker
- Ramakrishna Prabhu Gopalakrishnan Prosjektdeltaker
- Peter Csaba Huszthy Prosjektdeltaker
- Ida Jonson Prosjektdeltaker
- Hilde Omholt Prosjektdeltaker
- Ole Audun Haabeth Prosjektdeltaker
- Anders Tveita Prosjektdeltaker
- Bjarne Bogen Prosjektleder
- Peter Huszthy Postdoktorstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport